FDA approves pirtobrutinib for untreated CLL/SLL without 17p deletion based on BRUIN CLL-313 data. Read key nursing safety takeaways.
News|Articles|August 19, 2026
What Nurses Need to Know About FDA-Approved Iberdomide in Multiple Myeloma
Author(s)By ONN Staff
Fact checked by: Alex Biese
Oncology clinical trial nurse navigator Elise Curry, RN, breaks down the key clinical questions surrounding the FDA approval of oral iberdomide.
Advertisement
Advertisement
The FDA granted accelerated approval to iberdomide (Zenbexus, Bristol-Myers Squibb Company) combined with daratumumab and hyaluronidase-fihj and dexamethasone for adults with relapsed or refractory multiple myeloma (RRMM) who received at least one prior line of therapy, including a proteasome inhibitor and an immunomodulatory agent. This approval introduces the first approved cereblon E3 ligase modulator (CELMoD) agent, establishing a novel therapeutic class in the myeloma landscape.
Related to this article
Beth Faiman, PhD, and Sikander Ailawadhi, MD, discuss clinic workflows, safety checks, and at-home dosing potential for on-body isatuximab.
An FDA advisory panel voted to approve GRAIL's Galleri multi-cancer early detection test for adults 50+. Read key oncology nursing takeaways.
FDA approves belzutifan with lenvatinib for advanced clear cell RCC after PD-1/PD-L1 inhibitor failure. Review LITESPARK-011 data and nursing takeaways.
FDA approves lirafugratinib (Lyrfigtu) for FGFR2+ cholangiocarcinoma. Review REFOCUS trial data, 70 mg daily dosing, and nursing safety guidelines.
Beth Faiman, PhD, and Sikander Ailawadhi, MD, discuss clinical trials and nursing impacts of on-body isatuximab delivery in multiple myeloma.
FDA approves lutetium lu 177 dotatate (Bravnetsa) as bioequivalent to Lutathera for GEP-NETs. Review key nursing takeaways and safety guidelines.
FDA approves imlunestrant plus abemaciclib for ESR1-mutated, ER-positive, HER2-negative advanced or metastatic breast cancer after endocrine therapy.
Advertisement
Advertisement